Analyzing the progression of Alzheimer's disease (AD) is challenging due to lacking sensitivity in currently available measures. AD stages are typically defined based on cognitive cut-offs, but this results in heterogeneous patient groups. More accurate modeling of the continuous progression of the disease would enable more accurate patient prognosis. To address these issues, we propose a new multivariate continuous-time disease progression (MCDP) model. The model is formulated as a nonlinear mixed-effects model that aligns patients based on their predicted disease progression along a continuous latent disease timeline. The model is evaluated using long-term follow-up data from 2152 participants in the Alzheimer's Disease Neuroimaging Initi...
Clinical observations of patients with chronic diseases are often restricted in terms of duration. T...
Alzheimer's disease (AD) is characterised by a dynamic process of neurocognitive changes from normal...
IntroductionClinical trials on preclinical Alzheimer's disease are challenging because of the slow r...
Analyzing the progression of Alzheimer's disease (AD) is challenging due to lacking sensitivity in c...
Background: The characterizing symptom of Alzheimer disease (AD) is cognitive deterioration. While m...
Alzheimer's disease (AD) is a neurodegenerative condition that leads to dementia, and remains incura...
Mahesh N Samtani, Nandini Raghavan, Gerald Novak, Partha Nandy, Vaibhav A Narayan On behalf of the A...
Alzheimer's disease is the most common neurodegenerative disease and is characterized by the accumul...
ii As the Alzheimer’s disease process progresses in time measurements of cognitive functioning exhib...
To characterize the course of Alzheimer's disease (AD) over a longer time interval, we aimed to cons...
Alzheimer’s Disease is an irreversible disease that causes a decline in cognitive abilities and lea...
Abstract Background Alzheimer’s disease and related dementia (ADRD) are characterized by multiple an...
Alzheimer’s disease (AD) is the most common type of degenerative dementia, and the increasing preval...
OBJECTIVE: To consider the methods available to model Alzheimer's disease (AD) progression over time...
Mild cognitive impairment is a preclinical stage of Alzheimer's disease (AD). For effective treatmen...
Clinical observations of patients with chronic diseases are often restricted in terms of duration. T...
Alzheimer's disease (AD) is characterised by a dynamic process of neurocognitive changes from normal...
IntroductionClinical trials on preclinical Alzheimer's disease are challenging because of the slow r...
Analyzing the progression of Alzheimer's disease (AD) is challenging due to lacking sensitivity in c...
Background: The characterizing symptom of Alzheimer disease (AD) is cognitive deterioration. While m...
Alzheimer's disease (AD) is a neurodegenerative condition that leads to dementia, and remains incura...
Mahesh N Samtani, Nandini Raghavan, Gerald Novak, Partha Nandy, Vaibhav A Narayan On behalf of the A...
Alzheimer's disease is the most common neurodegenerative disease and is characterized by the accumul...
ii As the Alzheimer’s disease process progresses in time measurements of cognitive functioning exhib...
To characterize the course of Alzheimer's disease (AD) over a longer time interval, we aimed to cons...
Alzheimer’s Disease is an irreversible disease that causes a decline in cognitive abilities and lea...
Abstract Background Alzheimer’s disease and related dementia (ADRD) are characterized by multiple an...
Alzheimer’s disease (AD) is the most common type of degenerative dementia, and the increasing preval...
OBJECTIVE: To consider the methods available to model Alzheimer's disease (AD) progression over time...
Mild cognitive impairment is a preclinical stage of Alzheimer's disease (AD). For effective treatmen...
Clinical observations of patients with chronic diseases are often restricted in terms of duration. T...
Alzheimer's disease (AD) is characterised by a dynamic process of neurocognitive changes from normal...
IntroductionClinical trials on preclinical Alzheimer's disease are challenging because of the slow r...